3 results match your criteria: "Cairo University and Children's Cancer Hospital Egypt (57357)[Affiliation]"
Correlation of Genetic Polymorphism of CYP3A5 to Cyclophosphamide Efficacy and Toxicity in Rhabdomyosarcoma Pediatric Egyptian Cancer Patients.
Asian Pac J Cancer Prev
July 2024
Pharmacology and Toxicology Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
Article Synopsis
- - Rhabdomyosarcoma (RMS) is a significant type of soft tissue cancer in children, representing about 7% of pediatric cancers, with cyclophosphamide (CPA) as a main treatment; its effectiveness may be influenced by the CYP3A5 enzyme's genetic variations.
- - A study analyzed 150 pediatric RMS patients, genotyping specific non-functional CYP3A5 SNPs to explore their link to the drug’s efficacy and side effects, revealing that most patients were poor metabolizers.
- - The findings indicated a significant relationship between the CYP3A5 genotypes and the incidence of drug-related toxicity, such as hemorrhagic cystitis and nephrotoxicity, highlighting the importance of CYP
Efficacy and Toxicity of Vincristine and CYP3A5 Genetic Polymorphism in Rhabdomyosarcoma Pediatric Egyptian Patients.
Asian Pac J Cancer Prev
April 2024
Pharmacology and Toxicology Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
Background: Rhabdomyosarcoma (RMS) is a rare cancer that develops in soft tissue, particularly skeletal muscle tissue and occasionally hollow organs like the bladder or uterus. Vincristine (VCR) is the main therapy used in treatment of RMS, it is an alkaloid produced from vinca and it is one of the most commonly prescribed drugs in pediatric oncology for the treatment of a number of tumors. The CYP3A5 enzyme is responsible for vincristine metabolism.
View Article and Find Full Text PDFCOVID-19-Associated Pulmonary Fungal Infection among Pediatric Cancer Patients, a Single Center Experience.
J Fungi (Basel)
August 2022
Pediatric Oncology Department, National Cancer Institute, Cairo University and Children's Cancer Hospital Egypt (57357), Cairo 11311, Egypt.
Patients with COVID-19 are at risk of developing secondary complications such as invasive pulmonary aspergillosis and mucormycosis. This is a retrospective study including all cancer children diagnosed with COVID-19-associated pulmonary fungal infection (CAPFI) during the period 2020-2021. A total of 200 patients were diagnosed with COVID-19, out of which 21 (10%) patients were diagnosed with CAPFI, 19 patients (90%) with COVID-aspergillosis (CAPA), and 2 (10%) patients with COVID-mucormycosis (CAM).
View Article and Find Full Text PDF